PFF Walk series launched to raise funds and awareness for pulmonary fibrosis and interstitial lung disease

The Pulmonary Fibrosis Foundation (PFF) today announced the launch of its annual PFF Walk series, a nationwide effort to raise funds and awareness for pulmonary fibrosis (PF) and interstitial lung disease (ILD). More than 250,000 Americans are living with PF and ILD, progressive diseases that cause inflammation, scarring, or both, that damage the lung's ability to absorb oxygen from the air.

The PFF Walk will kick off on July 29 in Pittsburgh and will continue through October in cities across the U.S. -;

• 29 – North Shore Riverfront Park, Pittsburgh
• 5 – Liberty State Park, NYC Metro
• 9 – Little Marina Green, Bay Area
• 16 – Diversey Harbor, Chicago
• 30 – Virtual, National Walk Day
• 7 – National Harbor, Washington, D.C.
• 21 – The Sound at Cypress Waters, Dallas

The PFF Walk is a growing movement that inspires and empowers those whose lives have been affected by these debilitating diseases. Participants are energized by the opportunity to make a difference by fundraising and sharing their experiences with PF and ILD."

William T. Schmidt, President, and CEO of the PFF

The PFF Walk is a memorable experience and brings together people living with PF, caregivers and families, lung transplant recipients, and all community members. New this year, each Walk will include a Mission Moment that honors all attendees and provides a moment of remembrance for those who have been lost to pulmonary fibrosis.

Each Walk features two course options – 5K and one mile. Participants are encouraged to go at their own pace. The event will also include a variety of activities and entertainment, including music, food, and family fun.

Registration for the PFF Walk is free. Walkers who raise $100 or more will receive a commemorative PFF Walk t-shirt. To register or for more information, visit PFFWalk.org. A special thank you to the PFF Walk National Sponsors, Boehringer Ingelheim, CVS Specialty Pharmacy, Horizon Therapeutics and United Therapeutics.